Table 2.
Characteristics at Admission for Monoclonal Antibody Treatment
| Characteristics | Total Cohort, N = 47 |
|---|---|
| Symptoms | |
| Fever, n (%) | 15 (32) |
| Cough, n (%) | 25 (53) |
| Shortness of breath, n (%) | 3 (6) |
| Diarrhea, n (%) | 7 (15) |
| SARS-CoV-2 viral loada | |
| Day 0,b copies/mL, median (range) | 2,110,027 (1,000-153,798,962) |
| Day 7,c copies/mL, median (range) | 1,000 (0-10,000,000) |
| Monoclonal antibody treatment | |
| Casirivimab-imdevimab, n (%) | 16 (34) |
| Sotrovimab, n (%) | 31 (66) |
| SARS-CoV-2 variant | |
| Delta, n (%) | 8 (17) |
| Omicron, n (%) | 13 (28) |
| Gamma, n (%) | 1 (2) |
| Not available, n (%) | 25 (53) |
Abbreviation: SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
a
Polymerase chain reaction.
b
Day of monoclonal antibody treatment.
c
7-8 days after treatment.